A Multinational Randomized Phase III课件.pptVIP

下载本文档

10
0
约1.06万字
约 22页
2017-08-23 发布于广东
举报
版权申诉

A Multinational Randomized Phase III课件.ppt

1、本文档共22页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

* * * * * * * * * * * * Presented by: Presented by: Presented by: Presented by: Presented by: Presented by: Presented by: Presented by: A Multinational Randomized Phase III Trial with or without Consolidation Chemotherapy Using Docetaxel and Cisplatin after Concurrent Chemoradiation in Inoperable Stage III Non-small Cell Lung Cancer (CCheIN) Keunchil Park1, Jin Seok Ahn1, Myung-Ju Ahn1, Yong Chan Ahn1, Joo-Hang Kim2, Chang Geol Lee2, Eun Kyung Choi3, Kyu Chan Lee3, Ming Chen4, Dae Seog Heo5, Hoon-Kyo Kim6, Young Joo Min7, Jin-Hyoung Kang8, Jin Hyuck Choi9, Sang-We Kim10, Guangying Zhu11, Yi Long Wu12, Sung Rok Kim13, Kyung Hee Lee14, Hong Suk Song15 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 2Yonsei Cancer Center, Yonsei University Medical Center, 3Gachon University Gil Medical Center, 4Sun Yat-Sen University Cancer Center, 5Seoul National University Hospital, 6Catholic University St. Vincents Hospital, 7Ulsan University Hospital, 8Catholic University Seoul St. Mary’s Hospital, 9Ajou University Hospital, 10Asan Medical Center, 11Beijing Cancer Hospital, 12Guandong Province People’s Hospital, 13Inje University Sanggye Paik Hospital, 14Yeungnam University Medical Center, 15Keimyung University Dongsan Medical Center Disclosure Advisor/Consultant ; Astra-Zeneca, Astellas, AVEO, Boehringer Ingelheim, Clovis, Daiichi Sankyo, Eli Lilly, Hanmi, Kyowa Hakko Kirin, Novartis, Roche Research Fund; Astra-Zeneca, Sanofi-Aventis Presented by: Background The recommended treatment for inoperable stage III NSCLC is concurrent chemoradiotherapy (CCRT). Despite progress with combined-modality approach the prognosis of LA-NSCLC is still poor. Phase II trial (SWOG 9504) for the consolidation chemotherapy with docetaxel after CCRT with etoposide/cisplatin gave promising result. Phase III trial by Hoosier Oncology Group failed to demonstrate a benefit of consolidation chemotherapy after definitive CCRT (median OS 21.2 months for docetaxel arm compared